B6-hMASP2 Mouse
Product Name
B6-hMASP2 Mouse
Product ID
C001592
Strain Name
C57BL/6NCya-Masp2em1(hMASP2)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hMASP2 Mouse (Catalog C001592) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
MASP2
Gene Alias
sMAP, MAP-2, MAP19, MASP-2, MASP1P1
NCBI ID
Chromosome
Chr 1 (Human)
MGI ID
Datasheet
Strain Description
The MASP2 gene encodes MASP-2, a serum serine protease that serves as a key mediator in complement system activation. MASP-2 initiates the lectin pathway by forming complexes with pattern recognition molecules such as mannose-binding lectin (MBL) and ficolins. Upon pathogen recognition by MBL, MASP-2 is activated and subsequently cleaves complement components C4 and C2, leading to the generation of C3 convertase and triggering downstream complement activation. Beyond its role in the complement cascade, MASP-2 also contributes to the coagulation pathway by cleaving prothrombin to generate thrombin, thereby linking innate immunity and hemostasis [1]. Emerging evidence highlights the clinical significance of MASP2 gene polymorphisms, which are associated with altered susceptibility to infectious diseases and immune-related disorders. Reduced plasma levels of MASP-2 have been linked to increased vulnerability to HIV infection, while elevated MASP-2 activity may exacerbate inflammatory responses [2]. Given its pivotal role in immune regulation, MASP-2 has emerged as a promising therapeutic target. Inhibition of MASP-2 is currently under investigation as a potential strategy for treating a range of conditions, including IgA nephropathy (IgAN) [3], atypical hemolytic uremic syndrome (aHUS), and transplant-associated thrombotic microangiopathy (TA-TMA) [4].
The B6-hMASP2 mouse model, generated through precise gene editing technology, features the in situ replacement of part of the endogenous mouse Masp2 gene with the coding sequence (CDS) of human MASP2. Homozygous B6-hMASP2 mice are viable and fertile, providing a robust platform for studying the pathophysiology of autoimmune and infectious diseases. This model also serves as a valuable tool for the development and preclinical evaluation of MASP-2-targeted therapeutics, offering insights into both mechanistic and translational aspects of complement-mediated diseases.
Reference
Xu WD, Liu XY, Su LC, Huang AF. Association of MASP2 levels and MASP2 gene polymorphisms with systemic lupus erythematosus. J Cell Mol Med. 2020 Sep;24(18):10432-10443.
Li Z, Wang M, Zhong H, Huang X, Wu X, Zhang X, Wang J, Deng J, Chen M, Chen L, Tan H. Impact of MASP2 gene polymorphism and gene-tea drinking interaction on susceptibility to tuberculosis. Sci Rep. 2021 Mar 22;11(1):6544.
Filippone EJ, Gulati R, Farber JL. Contemporary review of IgA nephropathy. Front Immunol. 2024 Aug 12;15:1436923.
Elhadad S, Redmond D, Huang J, Tan A, Laurence J. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence. Clin Exp Immunol. 2023 Jul 21;213(2):252-264.
Strain Strategy
The coding sequence of exon 1 and part of intron 1 was replaced with the “Human MASP2 CDS-rBG pA” cassette.
Figure 1. Gene editing strategy of B6-hMASP2 mice.
Application Area
MASP2-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of autoimmune and infectious diseases.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
